Redx Pharma Plc is a biotech company listed on AIM that specializes in discovering and developing targeted medicines to fight cancer and fibrotic disease. Its team of 50 scientists is located at Alderley Park, Cheshire, the UK's leading life science campus, and is comprised of experts in medicinal chemistry, biology, and clinical development. The company's main focus is its lead oncology asset, RXC004, which is currently undergoing a phase 1 clinical trial for patients with advanced malignancies. RXC007, the company's ROCK2 selective inhibitor, is anticipated to enter clinical trials next year. The team has significant experience in biotech and large pharma, lending it a strong foundation in the industry.